Andrea E. Wahner Hendrickson MD

Andrea E. Wahner Hendrickson, M.D., is a clinician-investigator with an interest in developing and testing new treatments for cancer. She evaluates novel therapeutics that target signal transduction in malignancies; studies mechanisms of resistance to novel agents that prevent, inhibit or halt the development of tumors (anti-neoplastic agents); and works to assess the effects of novel anti-neoplastic agents on their intended targets in phase I clinical trials.

Dr. Wahner Hendrickson also has a specific interest in the pharmacogenomics of platinum-taxane chemotherapy for ovarian cancer. As part of the Mayo Clinic Phase I group and the National Institutes of Health (NIH)-funded Mayo Clinic Ovarian Cancer Specialized Program of Research Excellence (SPORE) grant, she is in the process of developing a preclinical, translational laboratory program specifically devoted to ovarian cancer, with the goal of streamlining the development of novel agents to benefit patients with cancer.